Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma

OBJECTIVE: To investigate the short-term clinical efficacy and safety of the Janus kinase inhibitor tofacitinib in patients with Nagashima-type palmoplantar keratoderma (NPPK). METHODS: A retrospective analysis was performed on 7 NPPK patients with a homozygous SERPINB7 c.796C>T mutation, treated with oral tofacitinib citrate (adults: 5 mg twice daily; children: 5 mg once daily). Efficacy and adverse events were evaluated at weeks 0, 4, 8, and 12. RESULTS: The cohort included 5 female and 2 male patients, including 2 children. The mean age at disease onset was 15.3 years, with onset at ≤ 10 years in 5 patients. All had palmoplantar keratosis; 2 had Achilles tendon and 3 wrist involvement. All patients had ineffective prior retinoid therapy. No adverse events occurred during tofacitinib treatment. Hyperkeratosis improved markedly in 4 (57%), mildly in 1 (14%), and showed no response in 2 (29%) patients. The mean keratotic severity score decreased from 6.89 to 4.25 (approx. 40% reduction). CONCLUSIONS: Tofacitinib may be effective for NPPK, but larger randomized controlled trials are required to confirm long-term efficacy and safety.

Authors

Institutions

Publication Details

Journal
JDDG Journal der Deutschen Dermatologischen Gesellschaft
Published
2026-11-16
DOI
https://doi.org/10.1111/ddg.70543
Primary Topic
Genetic and rare skin diseases.
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma

Fanzhang Meng, 徐东昭, Chen Li, Zhimin Lin et al.
2 links
JDDG Journal der Deutschen Dermatologischen Gesellschaft
Genetic and rare skin diseases.
article

Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma

Fanzhang Meng, 徐东昭, Chen Li, Zhimin Lin, Yuan Chen
article en

Abstract

OBJECTIVE: To investigate the short-term clinical efficacy and safety of the Janus kinase inhibitor tofacitinib in patients with Nagashima-type palmoplantar keratoderma (NPPK). METHODS: A retrospective analysis was performed on 7 NPPK patients with a homozygous SERPINB7 c.796C>T mutation, treated with oral tofacitinib citrate (adults: 5 mg twice daily; children: 5 mg once daily). Efficacy and adverse events were evaluated at weeks 0, 4, 8, and 12. RESULTS: The cohort included 5 female and 2 male patients, including 2 children. The mean age at disease onset was 15.3 years, with onset at ≤ 10 years in 5 patients. All had palmoplantar keratosis; 2 had Achilles tendon and 3 wrist involvement. All patients had ineffective prior retinoid therapy. No adverse events occurred during tofacitinib treatment. Hyperkeratosis improved markedly in 4 (57%), mildly in 1 (14%), and showed no response in 2 (29%) patients. The mean keratotic severity score decreased from 6.89 to 4.25 (approx. 40% reduction). CONCLUSIONS: Tofacitinib may be effective for NPPK, but larger randomized controlled trials are required to confirm long-term efficacy and safety.

JDDG Journal der Deutschen Dermatologischen Gesellschaft
Beijing University of Chinese Medicine (CN), Capital Medical University (CN), Southern University of Science and Technology (CN), ShenZhen People’s Hospital (CN), First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (CN), Beijing Hospital of Traditional Chinese Medicine (CN)
National Natural Science Foundation of China
Good health and well-being
Genetic and rare skin diseases.
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon